Targeted Duo Wins Again in BRAF-Mutant Colorectal Cancer

By News Health
1 hour Ago

(MedPage Today) — SAN FRANCISCO — Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated metastatic colorectal cancer led to a significant improvement in overall response rate (ORR), according…

Source link : https://www.medpagetoday.com/meetingcoverage/ascogi/119298

Author :

Publish date : 2026-01-06 19:27:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

First Transcatheter Coronary Bypass; Y Chromosome Loss & MI; GLP-1s vs Brain Bleeds

NHS England Names First Services for Online Hospital

The first quantum fluctuations set into motion a huge cosmic mystery

GLP-1 Drug Market Changes; Wegovy Pill Hits Shelves; Hypercortisolism Drug Rejected

Blinatumomab Consolidation Well Tolerated in MRD-Negative ALL

Passwords will be on the way out in 2026 as passkeys take over